These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35752614)

  • 41. A Case of Myocarditis Presenting With a Hyperechoic Nodule After the First Dose of COVID-19 mRNA Vaccine.
    Park S; You J
    J Korean Med Sci; 2022 Apr; 37(16):e131. PubMed ID: 35470603
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature.
    Lane S; Yeomans A; Shakir S
    BMJ Open; 2022 May; 12(5):e059223. PubMed ID: 35613761
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years.
    Hu M; Wong HL; Feng Y; Lloyd PC; Smith ER; Amend KL; Kline A; Beachler DC; Gruber JF; Mitra M; Seeger JD; Harris C; Secora A; Obidi J; Wang J; Song J; McMahill-Walraven CN; Reich C; McEvoy R; Do R; Chillarige Y; Clifford R; Cooper DD; Shoaibi A; Forshee R; Anderson SA
    JAMA Pediatr; 2023 Jul; 177(7):710-717. PubMed ID: 37213095
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute myocarditis following a third dose of COVID-19 mRNA vaccination in adults.
    Simone A; Herald J; Chen A; Nayak R; Shen YA; Lee MS
    Int J Cardiol; 2022 Oct; 365():41-43. PubMed ID: 35870635
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study.
    Naveed Z; Li J; Spencer M; Wilton J; Naus M; García HAV; Otterstatter M; Janjua NZ
    CMAJ; 2022 Nov; 194(45):E1529-E1536. PubMed ID: 36410749
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incidence, Clinical Presentation, and Management of Myocarditis following mRNA-Based Covid-19 Vaccines: A Brief Report.
    Saeed S; Käsk L; Rajani R; Larsen TH
    Cardiology; 2022; 147(4):406-412. PubMed ID: 35104821
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults.
    Harris DA; Hayes KN; Zullo AR; Mor V; Chachlani P; Deng Y; McCarthy EP; Djibo DA; McMahill-Walraven CN; Gravenstein S
    JAMA Netw Open; 2023 Aug; 6(8):e2326852. PubMed ID: 37531110
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database.
    Lee S; Jo H; Lee H; Lee H; Lee J; Kim HJ; Kang J; Jacob L; Smith L; Rahmati M; López Sánchez GF; Dragioti E; Jeon H; Cho JM; Choi Y; Park J; Woo S; Yon DK
    J Med Virol; 2024 Jun; 96(6):e29693. PubMed ID: 38859751
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy.
    Corrao G; Franchi M; Cereda D; Bortolan F; Leoni O; Vignati E; Pavesi G; Gori A
    BMC Infect Dis; 2022 Nov; 22(1):844. PubMed ID: 36371165
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine : A Case-Control Study.
    Lai FTT; Li X; Peng K; Huang L; Ip P; Tong X; Chui CSL; Wan EYF; Wong CKH; Chan EWY; Siu DCW; Wong ICK
    Ann Intern Med; 2022 Mar; 175(3):362-370. PubMed ID: 35073155
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.
    Andersson NW; Thiesson EM; Laursen MV; Mogensen SH; Kjær J; Hviid A
    BMJ; 2022 Jul; 378():e070483. PubMed ID: 35831006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Myocarditis and Pericarditis Related to mRNA COVID-19 Vaccination: A Case Report.
    María PLE; Diego RS; Jorge NR
    Curr Drug Saf; 2024; 19(1):154-158. PubMed ID: 36999413
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Global reports of myocarditis following COVID-19 vaccination: A systematic review and meta-analysis.
    Ahmed SK; Mohamed MG; Essa RA; Ahmed Rashad EA; Ibrahim PK; Khdir AA; Wsu ZH
    Diabetes Metab Syndr; 2022 Jun; 16(6):102513. PubMed ID: 35660931
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans.
    Dickerman BA; Madenci AL; Gerlovin H; Kurgansky KE; Wise JK; Figueroa Muñiz MJ; Ferolito BR; Gagnon DR; Gaziano JM; Cho K; Casas JP; Hernán MA
    JAMA Intern Med; 2022 Jul; 182(7):739-746. PubMed ID: 35696161
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand.
    Walton M; Pletzer V; Teunissen T; Lumley T; Hanlon T
    Drug Saf; 2023 Sep; 46(9):867-879. PubMed ID: 37556109
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand.
    Mahasing C; Doungngern P; Jaipong R; Nonmuti P; Chimmanee J; Wongsawat J; Boonyasirinant T; Wanlapakorn C; Leelapatana P; Yingchoncharoen T; Ngarmukos T; Chokephaibulkit K; Srimahachota S
    Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112661
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk of myocarditis after three doses of COVID-19 mRNA vaccines in the United States, 2020-2022: A self-controlled case series study.
    Lai D; Lim D; Lu J; Wang H; Huang T; Zhang YD
    J Evid Based Med; 2024 Mar; 17(1):65-77. PubMed ID: 38494781
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12-17 years.
    Guo BQ; Li HB; Yang LQ
    Vaccine; 2023 Jun; 41(28):4067-4080. PubMed ID: 37246067
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessing the temporal and cause-effect relationship between myocarditis and mRNA COVID-19 vaccines. A retrospective observational study.
    Bianchi FP; Rizzi D; Daleno A; Stefanizzi P; Migliore G; Tafuri S
    Int J Infect Dis; 2024 Apr; 141():106960. PubMed ID: 38365084
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acute cardiac side effects after COVID-19 mRNA vaccination: a case series.
    Freise NF; Kivel M; Grebe O; Meyer C; Wafaisade B; Peiper M; Zeus T; Schmidt J; Neuwahl J; Jazmati D; Luedde T; Bölke E; Feldt T; Jensen BEO; Bode J; Keitel V; Haussmann J; Tamaskovics B; Budach W; Fischer JC; Knoefel WT; Schneider M; Gerber PA; Pedoto A; Häussinger D; van Griensven M; Rezazadeh A; Flaig Y; Kirchner J; Antoch G; Schelzig H; Matuschek C
    Eur J Med Res; 2022 Jun; 27(1):80. PubMed ID: 35655235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.